Sunday, May 29th, 2022
- Plenary session 6: Cardiovascular complications in cancer patients
Chairs: B. Rocca (Italy), P. Angchaisuksiri (Thailand)
PL-21 - Evolving data on cardiovascular complications in cancer
H. Ten Cate (The Netherlands)
PL-22 - Cardiotoxic effects of antitumor agents: Pathogenetic mechanisms
A.D. Tselepis (Greece)
PL-23 - Optimizing antithrombotic therapy for atrial fibrillation in cancer
A. Tufano (Italy)
PL-24 - Clonal hematopoiesis and cardiovascular complications in cancer patients and survivors
J.J. Fuster (Spain)
Selected Abstract
- Debate: Duration of VTE treatment beyond 6 months: To continue or not to continue?
Chairs: S.C. Cannegieter (The Netherlands), A. Cohen (UK)
YES
A.Y.Y. Lee (Canada)
NO
M. Di Nisio (Italy)
- Plenary Session 7: Prevention and treatment of Cancer-Associated Thromboembolism
Chairs: A. Young (UK), R. Labianca (Italy)
PL-25 - Prevent and Treat VTE in cancer patients: ESMO guidelines
A. Falanga (Italy)
PL-26 - The impact of warfarin on overall survival in cancer patients with VTE
J. Zwicker (USA)
PL-27 - The impact of thromboprophylaxis on the survival of patients with pancreatic cancer
M. Karamouzis (Greece)
PL-28 - Cancer-Associated Non-Bacterial Thrombotic Endocarditis
A. Leader (Israel)
PL-29 - Risk benefit analysis of anticoagulation in elderly cancer patients
S. Noble (UK)
Selected Abstract